The Vaccination
Information about supplied vaccines, effectiveness and the vaccination rollouts
Characteristics of COVID-19 Vaccines
COVID-19 vaccines are effective in preventing severe illness and symptoms such as fever or coughs. Vaccination is expected to reduce the number of severe COVID-19 patients and deaths.
Some cases of side effects such as localized pain in the injected site, headache, fatigue, muscle and joint pain, and anaphylaxis (acute allergic reaction) after vaccination in some rare cases have been reported.
Through their pharmaceutical approvals, effectiveness and safety of vaccines for COVID-19 has been verified based on clinical trials and scientific findings.
Available Vaccines
- Pfizer Inc. (approved for people aged 12 years and older)
- Vaccine name: Comirnaty
Vaccine type: mRNA vaccine
Pharmaceutical approval: February 14, 2021
〈Primary vaccination series〉Number of times to administer: twice Vaccination interval: 21 days Inoculation target: aged 12 years and older
〈Booster dose〉Number of times to administer: once Inoculation target: aged 12 years and older
〈Booster dose〉Number of times to administer: twice Inoculation target: aged 60 years and older or aged 18 to 59 and have underlying illness, or others who are recognized by doctors as having a high risk of aggravation, or medical personnel or employees of senior citizen facilities, etc.
Click here
for details of the vaccine - Moderna Inc.
- Vaccine name: Spikevax
Vaccine type: mRNA vaccine
Pharmaceutical approval: May 21, 2021
〈Primary vaccination series〉Number of times to administer: twice Vaccination interval: 28 days Inoculation target: aged 12 years and older
〈Booster dose〉Number of times to administer: once Inoculation target: aged 18 years and older
〈Booster dose〉Number of times to administer: twice Inoculation target: aged 60 years and older or aged 18 to 59 and have underlying illness, or others who are recognized by doctors as having a high risk of aggravation, or medical personnel or employees of senior citizen facilities, etc.
Click here for details of the vaccine - AstraZeneca PLC * Supply stop is the end of September 2022
- Vaccine name: Vaxzevria
Vaccine type: virus vector vaccine
Pharmaceutical approval: May 21, 2021
〈Primary vaccination series〉Number of times to administer: twice Vaccination interval: 4～12 weeks (Interval of 8 weeks or more for maximum effect)
Inoculation target: In principle, aged 40 years and older
Click here for details of the vaccine - Pfizer Inc. (approved for children aged 5 to 11 years old)
- Vaccine name: Comirnaty for 5 to 11 years old
Vaccine type: mRNA vaccine
Pharmaceutical approval: January 21, 2022
〈Primary vaccination series〉Number of times to administer: twice Vaccination interval: 21 days Inoculation target: between the ages of 5 and 11
〈Booster dose〉Number of times to administer: once Inoculation target: between the ages of 5 and 11
Click here for details of the vaccine - Takeda Pharmaceutical Company Limited（Novavax Inc）
- Vaccine name: Nuvaxovid
Vaccine type: recombinant protein vaccine
Pharmaceutical approval: April 19, 2022
〈Primary vaccination series〉Number of times to administer: twice Vaccination interval: 21 days Inoculation target: aged 12 years and older
〈Booster dose〉Number of times to administer: once Inoculation target: aged 18 years and older
Click here for details of the vaccine
Vaccination rollouts in Japan (by prefecture)
Please refer to here.
Novel Coronavirus Vaccination Q&A Website
We answer the questions about the effectiveness of the novel coronavirus vaccines, their safety, and your eligibility.
